Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFM5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,318
Award facts
- Contract value 100% obligated
- $19,318.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,318.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUCALA 100 mg/ml syringes. The award, issued on December 17, 2025, with an ultimate completion date of December 18, 2025, carries no set-aside designation, indicating the contractor won this order through unrestricted federal procurement competition. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the federal military medical supply chain, having been registered in the System for Award Management since 2001 and demonstrating substantial contracting activity with the DLA's Medical Supply Chain division. The company's portfolio encompasses branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables, with NUCALA—an immunosuppressant biologic agent—representing the type of specialized pharmaceutical product the contractor routinely supplies to support DOD healthcare facilities. The IDC under which this delivery order was issued has a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting Department of Defense medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DR26FCFM5?
SPE2DR26FCFM5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FCFM5 worth?
The government has obligated $19,318 on SPE2DR26FCFM5.
Is contract SPE2DR26FCFM5 an order under another contract?
Yes. SPE2DR26FCFM5 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFM5 competed?
The extent of competition for SPE2DR26FCFM5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award